Skip to content

US · COCH · MEDICAL - DEVICES

Envoy Medical, Inc. (COCH) intrinsic value and stock valuation

$6.70as of 2026-11-21 · Mkt cap 14.23M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Envoy Medical, Inc. DCF and intrinsic value

InvestorsCraft values COCH with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from COCH’s statements →

Envoy Medical, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices White Bear Lake, MN 55110 envoymedical.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$240K
20202025
Net income
-$-23.76M
20202025
Free cash flow
-$-18.38M
20212025
Total equity
-$-11.77M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$240K$230K$320K$240K$310K
Operating income-$-22.27M-$-19.26M-$-18.36M-$-8.71M-$-6.87M
Net income-$-23.76M-$-20.8M-$-29.92M-$-15.92M-$-8.68M
EPSd-$-1.21M-$-1.11M-$-2.38M-$-1.57M-$-855.17K
Operating cash flow-$-18.2M-$-17.95M-$-17.09M-$-8.8M-$-6.94M
Capital expenditure-$-180K-$-980K-$-150K-$-220K-$-120K
Free cash flow-$-18.38M-$-18.93M-$-17.24M-$-9.02M-$-7.06M
Total assets$8.56M$11.5M$8.27M$2.56M$2.62M
Total debt$920K$19.7M$560K$34.5M$23.5M
Net debt-$-2.82M$14.2M-$-3.66M$34.4M$22.4M
Total equity-$-11.77M-$-18.84M-$-1.78M-$-36.2M-$-44.96M
Cash and short-term investments$3.74M$5.48M$4.22M$180K$1.12M
Income statement
20252024202320222021
Revenue$240K$230K$320K$240K$310K
Cost of revenue$870K$740K$790K$500K$770K
Gross profit-$-630K-$-520K-$-470K-$-260K-$-460K
Research and development expenses$12.5M$10.2M$8.96M$4.97M$3.94M
Selling, general and administrative expenses$9.15M$8.56M$8.93M$3.47M$2.47M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$21.6M$18.7M$17.9M$8.45M$6.41M
Cost and expenses$22.5M$19.5M$18.7M$8.94M$7.18M
Interest income$0.00$0.00$0.00$0.00$40K
Interest expense$1.59M$820K$0.00$0.00$0.00
Depreciation and amortization$300K$170K$130K$70K$70K
Ebitda-$-21.86M-$-19.81M-$-29.79M-$-15.85M-$-8.6M
Operating income-$-22.27M-$-19.26M-$-18.36M-$-8.71M-$-6.87M
Total other income/expenses, net-$-1.49M-$-1.54M-$-11.56M-$-7.22M-$-1.8M
Income before tax-$-23.76M-$-20.8M-$-29.92M-$-15.92M-$-8.68M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-23.76M-$-20.8M-$-29.92M-$-15.92M-$-8.68M
Weighted average shares outstanding$19.6M$18.8M$12.6M$10.2M$10.2M
Weighted average diluted shares outstanding$19.6M$18.8M$12.6M$10.2M$10.2M
Balance sheet
20252024202320222021
Cash and short-term investments$3.74M$5.48M$4.22M$180K$1.12M
Net receivables$30K$820K$70K$40K$90K
Inventory$1.55M$1.71M$1.4M$1.29M$1.06M
Total current assets$6.28M$9.38M$7.46M$1.65M$2.44M
Property, plant and equipment, net$1.92M$2.15M$810K$910K$190K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.28M$2.15M$810K$910K$190K
Total assets$8.56M$11.5M$8.27M$2.56M$2.62M
Accounts payable$2.92M$1.65M$1.55M$1M$660K
Short-term debt$170K$140K$160K$570K$0.00
Deferred revenue$0.00$0.00$0.00$10K$10K
Total current liabilities$11.6M$7.54M$7.29M$2.52M$1.38M
Long-term debt$740K$19.5M$400K$34M$23.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.76M$22.8M$2.76M$36.2M$46.2M
Capital lease obligations$0.00$940K$560K$690K$0.00
Total liabilities$20.3M$30.4M$10.1M$38.8M$47.6M
Common stock$0.00$0.00$0.00$0.00$1.39M
Retained earnings-$-313.4M-$-284.73M-$-257.26M-$-225.99M-$-210.06M
Accumulated other comprehensive income (loss)-$-120K-$-120K-$-120K-$-120K-$-110K
Total equity-$-11.77M-$-18.84M-$-1.78M-$-36.2M-$-44.96M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$920K$19.7M$560K$34.5M$23.5M
Net debt-$-2.82M$14.2M-$-3.66M$34.4M$22.4M
Cash flow statement
20252024202320222021
Net income-$-23.76M-$-22.45M-$-29.92M-$-15.92M-$-8.68M
Depreciation and amortization$300K$170K$130K$70K$70K
Stock-based compensation$90K$0.00$1.57M$0.00$0.00
Change in working capital$1.84M-$-640K-$-980K-$-160K-$-80K
Accounts receivable$770K-$-570K-$-200K$50K-$-20K
Inventory$130K-$-380K-$-10K-$-190K$60K
Accounts payable$1.39M-$-20K$550K$340K$230K
Net cash provided by operating activities-$-18.2M-$-17.95M-$-17.09M-$-8.8M-$-6.94M
Investments in property, plant and equipment-$-180K-$-980K-$-150K-$-220K-$-120K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-180K-$-980K-$-150K-$-220K-$-120K
Common stock issued$9.44M$3.56M$110K$90K$60K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-1.82M-$-2.45M$0.00$0.00$0.00
Net cash used for financing activities$16.6M$20.2M$21.3M$8.09M$8.06M
Net change in cash-$-1.74M$1.26M$4.04M$30K$990K
Cash at end of period$3.74M$5.48M$4.22M$180K$1.12M
Operating cash flow-$-18.2M-$-17.95M-$-17.09M-$-8.8M-$-6.94M
Capital expenditure-$-180K-$-980K-$-150K-$-220K-$-120K
Free cash flow-$-18.38M-$-18.93M-$-17.24M-$-9.02M-$-7.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Envoy Medical, Inc.

        Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.

        CEO
        Brent T. Lucas
        Employees
        43
        Beta
        1.86

        Explore

        Frequently asked questions

        What is the intrinsic value of Envoy Medical, Inc. (COCH)?

        Envoy Medical, Inc. (COCH) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is COCH undervalued?

        COCH trades at a price of $6.70 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.